U.S. FDA Grants Orphan Drug Designation To Zai Lab’s DLL3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
ZLAB•FDA grants orphan drug designation
- U.S. FDA grants orphan drug designation to Zai Lab’s DLL3-targeting ADC zocilurtatug pelitecan (Zoci) for the treatment of neuroendocrine carcinomas (NECs).
Source text: ID:nBw2B59f5a
Further company coverage: 9688.HK
